Baxter International Inc. Stock

Equities

BAX

US0718131099

Medical Equipment, Supplies & Distribution

Market Closed - Nyse 04:00:02 2024-04-17 pm EDT 5-day change 1st Jan Change
39.52 USD -0.13% Intraday chart for Baxter International Inc. -5.90% +2.22%
Sales 2024 * 15.11B Sales 2025 * 15.68B Capitalization 20.13B
Net income 2024 * 747M Net income 2025 * 960M EV / Sales 2024 * 1.94 x
Net Debt 2024 * 9.15B Net Debt 2025 * 8.02B EV / Sales 2025 * 1.8 x
P/E ratio 2024 *
21 x
P/E ratio 2025 *
17.5 x
Employees 60,000
Yield 2024 *
2.92%
Yield 2025 *
3.16%
Free-Float 74.06%
More Fundamentals * Assessed data
Dynamic Chart
Exact Sciences Names Aaron Bloomer CFO MT
Baxter International Inc. Expands Pharmaceuticals Portfolio with New Injectable Products in the U.S CI
Pfizer, Baxter, Thermo Fisher, Others FTC Cautioned to Extend Merger Review Period MT
Citigroup Raises Price Target on Baxter International to $44 From $41, Keeps Neutral Rating MT
Baxter International Receives US FDA Clearance for Novum IQ Large Volume Infusion Pump MT
Baxter International Inc. Announces U.S. FDA Clearance of Novum IQ Large Volume Infusion Pump and Dose IQ Safety Software, Advancing Connected and Intelligent Infusion Therapy CI
Baxter International Files Definitive Proxy Statement with Securities and Exchange Commission CI
Baxter International Inc. Enters into Fourth Amendment to the Existing $4.0 Billion Term Loan Credit Facility CI
Baxter International Receives a Shareholder Proposal from John Chevedden CI
Dialysis providers gain as investors focus on cardiac benefits after Ozempic's latest data RE
Baxter International Now Considering Sale of Kidney Care Business to Private Equity Investors MT
Dialysis firms gain as Ozempic kidney trial data disappoints RE
Transcript : Baxter International Inc. Presents at 45th Annual Raymond James Institutional Investors Conference 2024, Mar-04-2024 04:00 PM
Baxter International Provides an Update on the Planned Separation of its Kidney Care Business CI
Transcript : Baxter International Inc. Presents at Citi?s 2024 Unplugged Medtech and Life Sciences Access Day, Feb-29-2024 11:00 AM
More news
1 day-0.13%
1 week-5.90%
Current month-7.53%
1 month-5.02%
3 months+2.15%
6 months+24.12%
Current year+2.22%
More quotes
1 week
39.35
Extreme 39.35
41.90
1 month
39.35
Extreme 39.35
43.99
Current year
37.87
Extreme 37.87
44.01
1 year
31.01
Extreme 31.01
50.21
3 years
31.01
Extreme 31.01
89.70
5 years
31.01
Extreme 31.01
95.19
10 years
31.01
Extreme 31.01
95.19
More quotes
Managers TitleAgeSince
Chief Executive Officer 61 15-09-30
Director of Finance/CFO 54 23-10-17
Chief Tech/Sci/R&D Officer - 16-12-31
Members of the board TitleAgeSince
Director/Board Member 73 17-02-05
Director/Board Member 64 22-05-09
Director/Board Member 64 19-02-17
More insiders
Date Price Change Volume
24-04-17 39.52 -0.13% 2,800,139
24-04-16 39.57 -1.17% 2,658,887
24-04-15 40.04 -0.72% 3,062,144
24-04-12 40.33 -4.25% 4,126,975
24-04-11 42.12 +0.29% 3,060,574

Delayed Quote Nyse, April 17, 2024 at 04:00 pm EDT

More quotes
Baxter International Inc. specializes in the development, manufacturing and marketing of medical devices and medications intended for healthcare professionals. Net sales break down by family of products as follows: - medicines and medical devices (33.8%): products intended for treating hemophilia (substitution clotting factors) and immune deficiencies (multi-purpose immunoglobins), and used in intensive care (human albumin) and biosurgery (fibrin adhesive, surgical gel, bone substitutes, hemostatic compresses, etc.); - kidney dialysis drugs and equipment (30.1%); - systems for delivering medications and intravenous therapy (15.2%): used in the fields of anesthesia, oncology (chemotherapy and radiation), parenteral nutrition, etc.; - other (20.1%). Export accounts for 52.7% of net sales.
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
17
Last Close Price
39.52 USD
Average target price
47.4 USD
Spread / Average Target
+19.94%
Consensus